BreathEazy
Respiratory relief for cats, dogs and horses
Press and News
Henry Schein
BreathEazy has just formed a strategic alliance with Henry Schein, the largest veterinary wholesaler in Europe. With the worldwide awareness of the Aero range of veterinary products and their effectiveness in treating respiratory disease, veterinarians Europe wide now have overnight access to these products. For a current list of veterinary distributors of the Aero range of products, please click here (veterinarians only)
Vetman - Finland
Breatheazy is delighted to announce a new partnership with VetMan in Finland who will be distributing the Aero range of products. This new distributor in Finland means that BreathEazy now has a presence in thirteen countries world wide.
New Product Range
Following extensive testing and research, the AeroKat and AeroDawg aerosol chambers have been improved with the following features: -
- Patented Flow-Vu device which shows when the patient is taking therapeutic breaths
- Antistatic chamber body increasing aerosol medication's availability leading to an increase in efficacy
 |
|
| AeroHippus equine system | |
 |
Additionally we are delighted to announce the launch of a new product, the AeroHippus equine system. This cost effective alternative to the AeroMask equine system boasts the following features: -
- Designed by veterinary respiratory specialist for horses
- Low initial investment
- Portable design
- Antistatic chamber body gives greater medication availability compared to other products
- Patented Flow-Vu system shows when medication is being inhaled effectively
- Cost effective alternative to the AeroMask equine system
- Replacement/spare masks available
- (Suitable for MDI medication only)
Download product brochures: -
- AeroKat FAC with Flow-Vu.pdf (2.3MB)
- AeroDawg CAC with Flow-Vu.pdf (1.03MB)
- AeroHippus ES with Flow-Vu.pdf (1MB)
(You will need Adobe Acrobat - get it here)
CentraVet
BreathEazy is delighted to announce a new strategic partnership with CentraVet, the premier veterinary wholesaler in France.
Management of 13 cases of canine respiratory disease using inhaled corticosteroids (Veterinarian only)
Nick Bexfield et al discuss the value of inhaled corticosteroids in the management of chronic inflammatory airway disease in dogs.
Click here to read more...
Inhaled flunisolide suppresses the hypothalamic-pituitary-adrenocortical axis, but has minimal systemic immune effects in healthy cats (Veterinarian only)
Carol R Reinero et al. discuss the effects of inhaled flunisolide on both the hypothalamic-pituitary adrenocortical axis and the systemic immune system.
Read the abstract here...
Feline asthma - a review and new insights (Veterinarian only)
R.A. Hirt presents a comprehensive review of both the current understanding and treatment protocols of feline asthma. The article also goes on to discuss current research into the disease and gives a preview of future therapeutics.
Click here to read more...
Self assessment - a case presentation on feline asthma (Veterinarians only)
Nick Bexfield BVetMed CertSAM MRCVS from Queen's Veterinary School, Cambridge University gives a case presentation on a four year old cat with feline asthma.
Read the full article (220Kb) here...
The 24 h duration of bronchodilator action of the salmeterol/fluticasone combination inhaler (Veterinarian only)
Masoli et al discuss the use of a long acting beta agonist (salmeterol) in providing 24 hour bronchodilation for human asthma patients. Their conclusion was that the single evening administration of salmeterol resulted in a duration of bronchodilation of at least 24 h, with the abolition of the accentuated biphasic circadian variation in airway tone observed in asthma.
Read the abstract here...
Moderate dose inhaled corticosteroids plus salmeterol versus higher doses of inhaled corticosteroids in symptomatic asthma. (Veterinarian only)
Masoli, Weatherall, Holt and Beasley from the Medical Institute of New Zealand discuss the use of a long acting beta agonist in conjunction with inhaled corticosteroids in symptomatic human asthma patients. Their conclusion is that the addition of a LABA (salmeterol) to moderate doses of a ICS (fluticasone) results in a significantly greater clinical benefit than increasing the dose of ICS by twofold or more.
Read the abstract here...